Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
Launched by ALLERGAN · Nov 17, 2010
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of primary open-angle glaucoma that has never been treated
- • Visual Acuity 20/60 or better in each eye
- Exclusion Criteria:
- • Eye surgery within 3 months
- • Any refractive eye surgery
- • Contraindication to beta-adrenoceptor antagonist therapy (eg, chronic obstructive pulmonary disease \[COPD\], bronchial asthma, sinus bradycardia, heart block, history of severe myocardial infarction \[heart attack\])
- • Eye inflammation or eye infection within 3 months
- • Eye trauma within 6 months
- • Oral, injectable, or topical ophthalmic steroids within 21 days or anticipated use during study
About Allergan
Allergan, a global leader in pharmaceutical innovation, specializes in developing and commercializing a diverse portfolio of advanced therapeutic and aesthetic products. With a commitment to improving the health and well-being of patients, Allergan conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies across various medical fields, including ophthalmology, dermatology, and neuroscience. The company is dedicated to adhering to the highest ethical standards and regulatory guidelines, ensuring that its research not only advances medical science but also meets the needs of healthcare providers and patients worldwide. Through strategic collaborations and a focus on scientific excellence, Allergan continues to drive advancements in treatment options and enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Coimbra, , Portugal
Patients applied
Trial Officials
Medical Director
Study Director
Allergan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials